28 June 2012 - It was reported today that BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a specialty pharmaceutical company, has announced positive results of a completed pharmacokinetic study examining the effects of multiple BEMA Buprenorphine/Naloxone (BNX) films administered concurrent...

 

 

 

You must be logged in to view the whole article.
Click here if you require signing up